Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 601 to 615 of 1240 results for pain

  1. Risankizumab for previously treated moderately to severely active Crohn's disease (TA888)

    Evidence-based recommendations on risankizumab (Skyrizi) for previously treated moderately to severely active Crohn's disease in people 16 years and over.

  2. Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA768)

    Evidence-based recommendations on upadacitinib (Rinvoq) for treating active psoriatic arthritis in adults.

  3. Adalimumab and dexamethasone for treating non-infectious uveitis (TA460)

    Evidence-based recommendations on adalimumab (Humira) and dexamethasone (Ozurdex) for treating non-infectious uveitis in adults.

  4. The Juxta CURES adjustable compression system for treating venous leg ulcers (MIB25)

    NICE has developed a medtech innovation briefing (MIB) on the Juxta CURES adjustable compression system for treating venous leg ulcers

  5. LARS for reconstructing damaged intra-articular cruciate knee ligaments (MIB30)

    NICE has developed a medtech innovation briefing (MIB) on LARS for reconstructing damaged intra-articular cruciate knee ligaments

  6. Myocardial perfusion scintigraphy for the diagnosis and management of angina and myocardial infarction (TA73)

    Evidence-based recommendations on myocardial perfusion scintigraphy for diagnosing and managing angina and myocardial infarction in adults.

  7. Pouchitis: rifaximin (ESUOM30)

    Summary of the evidence on rifaximin for treating pouchitis to inform local NHS planning and decision-making

  8. Electrochemotherapy for metastases in the skin from tumours of non-skin origin and melanoma (HTG305)

    Evidence-based recommendations on electrochemotherapy for metastases in the skin from tumours of non-skin origin and melanoma. This involves applying short, powerful pulses of electricity to the tumour, allowing an anticancer drug to pass through into the cells.

  9. Percutaneous endoscopic colostomy (HTG105)

    Evidence-based recommendations on percutaneous endoscopic colostomy. This involves placing a plastic tube in the bowel that runs back through a small opening in the abdomen to allow waste to pass through to a drainage bag worn outside the body.

  10. Focal therapy using high-intensity focused ultrasound for localised prostate cancer (HTG667)

    Evidence-based recommendations on focal therapy using high-intensity focused ultrasound for localised prostate cancer. This involves using high-intensity focused ultrasound to heat up and destroy only the areas of the prostate with cancer (focal therapy). The aim is to destroy the cancer while reducing damage to healthy prostate tissue.

  11. Percutaneous thoracic duct embolisation for persistent chyle leak (HTG666)

    Evidence-based recommendations on percutaneous thoracic duct embolisation for persistent chyle leak. In this procedure, under general anaesthesia, ultrasound and X-rays are used to create an image of the thoracic duct and find the leak. Then, using a needle, a tube is inserted through the abdominal wall (percutaneous) and guided into the thoracic duct. Small metal coils and medical glue are inserted through the tube and used to plug the leak (embolisation). The aim is to stop the leak.

  12. Percutaneous transluminal renal sympathetic denervation for resistant hypertension (HTG662)

    Evidence-based recommendations on percutaneous transluminal renal sympathetic denervation for resistant hypertension. This involves inserting a device through the skin (percutaneous) into an artery in the thigh and then into the renal arteries (transluminal). It sends radio or sound waves to destroy the nerves in the renal arteries (sympathetic denervation). The aim is to lower blood pressure.

  13. The MIST Therapy system for the promotion of wound healing (HTG267)

    Evidence-based recommendations on the MIST Therapy system for the promotion of wound healing.

  14. Sutureless aortic valve replacement for aortic stenosis (HTG483)

    Evidence-based recommendations on sutureless aortic valve replacement for aortic stenosis in adults. This involves removing the narrowed aortic valve and replacing it with an artificial valve that holds itself in place.

  15. Selective internal radiation therapy for unresectable colorectal metastases in the liver (HTG542)

    Evidence-based recommendations on selective internal radiation therapy for unresectable colorectal metastases in the liver in adults. This involves injecting beads that emit radiation directly into the tumour.